Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly has a lot going for it ... Lilly was also working on something else in the background. As Novo Nordisk did, Lilly developed an alternative version of its diabetes drug -- Zepbound ...

th { background-color: #293a5a ... Upon a comprehensive analysis of Eli Lilly, the following trends can be discerned: The Price to Earnings ratio of 112.95 for this company is 4.17x above the ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

th { background-color: #293a5a ... Through an analysis of Eli Lilly, we can infer the following trends: At 86.87, the stock's Price to Earnings ratio significantly exceeds the industry average ...

On May 16, Eli Lilly and Company (NYSE ... working on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including ...

Eli Lilly & Co. said Tuesday it’s cutting ... as there were shortages and a high patient need. Against that background, Lilly ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly LLY0.49%increase; green up pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.